Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Galapagos stock | $118.12

Own Galapagos stock in just a few minutes.

Fact checked

Galapagos NV is a biotechnology business based in the US. Galapagos shares (GLPG) are listed on the NASDAQ and all prices are listed in US Dollars. Galapagos employs 1,407 staff and has a market cap (total outstanding shares value) of USD$6.5 billion.

How to buy shares in Galapagos

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Galapagos. Find the stock by name or ticker symbol: GLPG. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Galapagos reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$118.12, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Galapagos, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Galapagos. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Galapagos share price

Use our graph to track the performance of GLPG stocks over time.

Galapagos shares at a glance

Information last updated 2020-12-26.
Latest market closeUSD$118.12
52-week rangeUSD$94.53 - USD$274.03
50-day moving average USD$117.4403
200-day moving average USD$152.3519
Wall St. target priceUSD$118.52
PE ratio 60.6469
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.686

Buy Galapagos shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Forex
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, ETFs
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stocks, Bonds
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Galapagos stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Galapagos price performance over time

Historical closes compared with the close of $118.12 from 2020-12-09

1 week (2021-01-12) 15.18%
1 month (2020-12-22) 20.62%
3 months (2020-10-20) -10.37%
6 months (2020-07-20) -44.69%
1 year (2020-01-18) N/A
2 years (2019-01-18) 12.76%
3 years (2018-01-19) 5.05%
5 years (2016-01-20) 122.16%

Is Galapagos under- or over-valued?

Valuing Galapagos stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Galapagos's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Galapagos's P/E ratio

Galapagos's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 61x. In other words, Galapagos shares trade at around 61x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Galapagos financials

Gross profit TTM USD$468.6 million
Return on assets TTM -2.01%
Return on equity TTM -13.84%
Profit margin -70.9%
Book value $25.493
Market capitalisation USD$6.5 billion

TTM: trailing 12 months

Shorting Galapagos shares

There are currently 964,153 Galapagos shares held short by investors – that's known as Galapagos's "short interest". This figure is 10.5% down from 1.1 million last month.

There are a few different ways that this level of interest in shorting Galapagos shares can be evaluated.

Galapagos's "short interest ratio" (SIR)

Galapagos's "short interest ratio" (SIR) is the quantity of Galapagos shares currently shorted divided by the average quantity of Galapagos shares traded daily (recently around 116584.40145103). Galapagos's SIR currently stands at 8.27. In other words for every 100,000 Galapagos shares traded daily on the market, roughly 8270 shares are currently held short.

However Galapagos's short interest can also be evaluated against the total number of Galapagos shares, or, against the total number of tradable Galapagos shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Galapagos's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Galapagos shares in existence, roughly 10 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Galapagos shares, roughly 0 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Galapagos.

Find out more about how you can short Galapagos stock.

Galapagos share dividends

We're not expecting Galapagos to pay a dividend over the next 12 months.

Galapagos share price volatility

Over the last 12 months, Galapagos's shares have ranged in value from as little as $94.53 up to $274.03. A popular way to gauge a stock's volatility is its "beta".

GLPG.US volatility(beta: 0.54)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Galapagos's is 0.5401. This would suggest that Galapagos's shares are less volatile than average (for this exchange).

Galapagos overview

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sjögren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site